PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
PACIRA BIOSCIENCES, INC. (PCRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 433.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 265.40K shares, a 64.58% increase year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 167.59K shares, a 33.90% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 77.56K shares, a 74.66% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 261.71K shares, a 37.08% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 754.08K shares, a 46.68% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 1.41M shares, a 203.53% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 465.94K shares, a 1186.92% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 36.21K shares, a 43.87% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 265.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 433.00K shares 10-Q · filed 2026-08-04 | 510.55K shares derived: sum of 3 quarters · filed 2026-08-04 | 772.26K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 167.59K shares 10-Q · filed 2026-04-30 | 245.15K shares derived: sum of 2 quarters · filed 2026-04-30 | 506.86K shares derived: sum of 3 quarters · filed 2026-04-30 | 668.12K shares derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-12-31 | 77.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 339.27K shares derived: sum of 2 quarters · filed 2026-02-26 | 500.53K shares derived: sum of 3 quarters · filed 2026-02-26 | 754.08K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 261.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 422.97K shares derived: sum of 2 quarters · filed 2025-11-06 | 676.53K shares 10-Q · filed 2025-11-06 | 982.53K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 161.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 414.81K shares 10-Q · filed 2025-08-05 | 720.82K shares derived: sum of 3 quarters · filed 2025-08-05 | 1.14M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 253.56K shares 10-Q · filed 2025-05-08 | 559.56K shares derived: sum of 2 quarters · filed 2025-05-08 | 975.52K shares derived: sum of 3 quarters · filed 2025-05-08 | 1.42M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 306.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 721.97K shares derived: sum of 2 quarters · filed 2025-02-27 | 1.17M shares derived: sum of 3 quarters · filed 2025-02-27 | 1.41M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 415.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 863.20K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.11M shares 10-Q · filed 2024-11-06 | 1.23M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 447.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 692.33K shares 10-Q · filed 2024-07-30 | 818.70K shares derived: sum of 3 quarters · filed 2024-07-30 | 1.07M shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 245.08K shares 10-Q · filed 2024-05-07 | 371.46K shares derived: sum of 2 quarters · filed 2024-05-07 | 622.59K shares derived: sum of 3 quarters · filed 2024-05-07 | 682.65K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 126.38K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 377.50K shares derived: sum of 2 quarters · filed 2024-02-29 | 437.57K shares derived: sum of 3 quarters · filed 2024-02-29 | 465.94K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 251.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 311.19K shares derived: sum of 2 quarters · filed 2023-11-02 | 339.56K shares 10-Q · filed 2023-11-02 | 351.32K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | 60.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 88.44K shares 10-Q · filed 2023-08-02 | 100.20K shares derived: sum of 3 quarters · filed 2024-02-29 | 111.59K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | 28.38K shares 10-Q · filed 2023-05-03 | 40.13K shares derived: sum of 2 quarters · filed 2024-02-29 | 51.53K shares derived: sum of 3 quarters · filed 2024-02-29 | 51.53K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | 11.76K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 23.15K shares derived: sum of 2 quarters · filed 2024-02-29 | 23.15K shares derived: sum of 3 quarters · filed 2024-02-29 | 36.21K shares 10-K · filed 2024-02-29 |
| 2022-09-30 | 11.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 11.39K shares derived: sum of 2 quarters · filed 2022-11-03 | 24.45K shares 10-Q · filed 2022-11-03 | 46.54K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 13.05K shares 10-Q · filed 2022-08-03 | 35.14K shares derived: sum of 3 quarters · filed 2024-02-29 | 55.44K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 13.05K shares 10-Q · filed 2022-05-04 | 35.14K shares derived: sum of 2 quarters · filed 2024-02-29 | 55.44K shares derived: sum of 3 quarters · filed 2024-02-29 | 70.94K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 22.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 42.39K shares derived: sum of 2 quarters · filed 2024-02-29 | 57.89K shares derived: sum of 3 quarters · filed 2024-02-29 | 64.50K shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 20.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 35.80K shares derived: sum of 2 quarters · filed 2021-11-03 | 42.42K shares 10-Q · filed 2021-11-03 | 117.27K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 15.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 22.12K shares 10-Q · filed 2021-08-03 | 96.97K shares derived: sum of 3 quarters · filed 2023-02-28 | 109.16K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 6.62K shares 10-Q · filed 2021-05-04 | 81.47K shares derived: sum of 2 quarters · filed 2023-02-28 | 93.66K shares derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | 74.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 87.05K shares derived: sum of 2 quarters · filed 2023-02-28 | 119.03K shares 10-K · filed 2023-02-28 | |
| 2020-09-30 | 12.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | 44.18K shares 10-Q · filed 2020-10-30 | ||
| 2020-06-30 | 31.98K shares 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |